Next Step in Incretin-Based Therapy: From Single to Dual Agonism
The twin epidemics of Type 2 diabetes (T2D) and obesity will continue to bring significant health challenges in the coming decades. Randomised controlled trials of glucagon-like peptide 1 (GLP-1)-based therapies showed high glycaemic efficacy with clinically meaningful weight loss, and have been co...
I tiakina i:
| Ngā kaituhi matua: | , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
European Medical Journal
2022-07-01
|
| Rangatū: | European Medical Journal Diabetes |
| Urunga tuihono: | https://www.emjreviews.com/diabetes/article/next-step-in-incretin-based-therapy-from-single-to-dual-agonism/ |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|